De novo abnormalities identified by fluorescence in situ hybridization during follow-up confer poor prognosis in Chinese multiple myeloma
BackgroundAlthough there is evolving consensus to re-evaluate cytogenetic features during follow-up in multiple myeloma (MM), longitudinal studies on cytogenetic evolution in Chinese MM patients are still lacking. Our aim was to highlight the importance of ongoing monitoring of cytogenetic character...
Saved in:
| Main Authors: | , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-03-01
|
| Series: | Frontiers in Medicine |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fmed.2025.1536825/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850032468766228480 |
|---|---|
| author | Shumin Chen Lu Gao Lin Feng Zheng Wang Ye Li Qing Liu Wenjie Song Shu Kong Yang Liu Jin Lu Yingjun Chang Xiaojun Huang Yueyun Lai |
| author_facet | Shumin Chen Lu Gao Lin Feng Zheng Wang Ye Li Qing Liu Wenjie Song Shu Kong Yang Liu Jin Lu Yingjun Chang Xiaojun Huang Yueyun Lai |
| author_sort | Shumin Chen |
| collection | DOAJ |
| description | BackgroundAlthough there is evolving consensus to re-evaluate cytogenetic features during follow-up in multiple myeloma (MM), longitudinal studies on cytogenetic evolution in Chinese MM patients are still lacking. Our aim was to highlight the importance of ongoing monitoring of cytogenetic characteristics and shed light on the implications of clonal evolution in Chinese MM patients.Patients and methodsThe clinical data of 230 MM patients were retrospectively analyzed, including 100 patients were continuously monitored for cytogenetic abnormalities by fluorescence in situ hybridization (FISH).Results49 out of 100 patients acquired de novo FISH abnormalities during follow-up, which were associated with disease progression (p = 0.003) and inferior progression free survival (PFS) (median 31 vs. 51 months, p = 0.032). Patients with ≥2 de novo FISH abnormalities had poorer PFS (median 24 vs. 45 months, p = 0.003) when compared to those with l or no de novo FISH abnormality. Patients who acquired new abnormalities within 31 months since diagnosis had significantly worse PFS (median: 20 vs. 41 months, p < 0.001) and Overall Survival (OS) (median: 61 vs. 100 months, p = 0.008) compared to those who acquired new abnormalities after 31 months. When gain/amp 1q21, del(17p), t(4;14), and t(14;16) were classified as high risk abnormalities (HRA), patients with ≥2 HRA had a shorter PFS (median 28 vs. 49 months, p = 0.038) and OS (median 75 vs. 107 months, p = 0.040) when compared to those without HRA.ConclusionRe-evaluation of cytogenetic characteristics by serial FISH tests is important in MM patients. De novo FISH abnormalities during follow-up are adverse prognostic factors, especially when ≥2 new FISH anomalies and acquired new abnormalities within 31 months since diagnosis are presented, and the presence of ≥2 HRA during the disease process are associated with poor survival in Chinese MM patients. |
| format | Article |
| id | doaj-art-401cf4d03bc54c2092ed878c35c94eb3 |
| institution | DOAJ |
| issn | 2296-858X |
| language | English |
| publishDate | 2025-03-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Medicine |
| spelling | doaj-art-401cf4d03bc54c2092ed878c35c94eb32025-08-20T02:58:37ZengFrontiers Media S.A.Frontiers in Medicine2296-858X2025-03-011210.3389/fmed.2025.15368251536825De novo abnormalities identified by fluorescence in situ hybridization during follow-up confer poor prognosis in Chinese multiple myelomaShumin ChenLu GaoLin FengZheng WangYe LiQing LiuWenjie SongShu KongYang LiuJin LuYingjun ChangXiaojun HuangYueyun LaiBackgroundAlthough there is evolving consensus to re-evaluate cytogenetic features during follow-up in multiple myeloma (MM), longitudinal studies on cytogenetic evolution in Chinese MM patients are still lacking. Our aim was to highlight the importance of ongoing monitoring of cytogenetic characteristics and shed light on the implications of clonal evolution in Chinese MM patients.Patients and methodsThe clinical data of 230 MM patients were retrospectively analyzed, including 100 patients were continuously monitored for cytogenetic abnormalities by fluorescence in situ hybridization (FISH).Results49 out of 100 patients acquired de novo FISH abnormalities during follow-up, which were associated with disease progression (p = 0.003) and inferior progression free survival (PFS) (median 31 vs. 51 months, p = 0.032). Patients with ≥2 de novo FISH abnormalities had poorer PFS (median 24 vs. 45 months, p = 0.003) when compared to those with l or no de novo FISH abnormality. Patients who acquired new abnormalities within 31 months since diagnosis had significantly worse PFS (median: 20 vs. 41 months, p < 0.001) and Overall Survival (OS) (median: 61 vs. 100 months, p = 0.008) compared to those who acquired new abnormalities after 31 months. When gain/amp 1q21, del(17p), t(4;14), and t(14;16) were classified as high risk abnormalities (HRA), patients with ≥2 HRA had a shorter PFS (median 28 vs. 49 months, p = 0.038) and OS (median 75 vs. 107 months, p = 0.040) when compared to those without HRA.ConclusionRe-evaluation of cytogenetic characteristics by serial FISH tests is important in MM patients. De novo FISH abnormalities during follow-up are adverse prognostic factors, especially when ≥2 new FISH anomalies and acquired new abnormalities within 31 months since diagnosis are presented, and the presence of ≥2 HRA during the disease process are associated with poor survival in Chinese MM patients.https://www.frontiersin.org/articles/10.3389/fmed.2025.1536825/fullmultiple myelomasurvivalhigh-riskclonal evolutioncytogenetics |
| spellingShingle | Shumin Chen Lu Gao Lin Feng Zheng Wang Ye Li Qing Liu Wenjie Song Shu Kong Yang Liu Jin Lu Yingjun Chang Xiaojun Huang Yueyun Lai De novo abnormalities identified by fluorescence in situ hybridization during follow-up confer poor prognosis in Chinese multiple myeloma Frontiers in Medicine multiple myeloma survival high-risk clonal evolution cytogenetics |
| title | De novo abnormalities identified by fluorescence in situ hybridization during follow-up confer poor prognosis in Chinese multiple myeloma |
| title_full | De novo abnormalities identified by fluorescence in situ hybridization during follow-up confer poor prognosis in Chinese multiple myeloma |
| title_fullStr | De novo abnormalities identified by fluorescence in situ hybridization during follow-up confer poor prognosis in Chinese multiple myeloma |
| title_full_unstemmed | De novo abnormalities identified by fluorescence in situ hybridization during follow-up confer poor prognosis in Chinese multiple myeloma |
| title_short | De novo abnormalities identified by fluorescence in situ hybridization during follow-up confer poor prognosis in Chinese multiple myeloma |
| title_sort | de novo abnormalities identified by fluorescence in situ hybridization during follow up confer poor prognosis in chinese multiple myeloma |
| topic | multiple myeloma survival high-risk clonal evolution cytogenetics |
| url | https://www.frontiersin.org/articles/10.3389/fmed.2025.1536825/full |
| work_keys_str_mv | AT shuminchen denovoabnormalitiesidentifiedbyfluorescenceinsituhybridizationduringfollowupconferpoorprognosisinchinesemultiplemyeloma AT lugao denovoabnormalitiesidentifiedbyfluorescenceinsituhybridizationduringfollowupconferpoorprognosisinchinesemultiplemyeloma AT linfeng denovoabnormalitiesidentifiedbyfluorescenceinsituhybridizationduringfollowupconferpoorprognosisinchinesemultiplemyeloma AT zhengwang denovoabnormalitiesidentifiedbyfluorescenceinsituhybridizationduringfollowupconferpoorprognosisinchinesemultiplemyeloma AT yeli denovoabnormalitiesidentifiedbyfluorescenceinsituhybridizationduringfollowupconferpoorprognosisinchinesemultiplemyeloma AT qingliu denovoabnormalitiesidentifiedbyfluorescenceinsituhybridizationduringfollowupconferpoorprognosisinchinesemultiplemyeloma AT wenjiesong denovoabnormalitiesidentifiedbyfluorescenceinsituhybridizationduringfollowupconferpoorprognosisinchinesemultiplemyeloma AT shukong denovoabnormalitiesidentifiedbyfluorescenceinsituhybridizationduringfollowupconferpoorprognosisinchinesemultiplemyeloma AT yangliu denovoabnormalitiesidentifiedbyfluorescenceinsituhybridizationduringfollowupconferpoorprognosisinchinesemultiplemyeloma AT jinlu denovoabnormalitiesidentifiedbyfluorescenceinsituhybridizationduringfollowupconferpoorprognosisinchinesemultiplemyeloma AT yingjunchang denovoabnormalitiesidentifiedbyfluorescenceinsituhybridizationduringfollowupconferpoorprognosisinchinesemultiplemyeloma AT xiaojunhuang denovoabnormalitiesidentifiedbyfluorescenceinsituhybridizationduringfollowupconferpoorprognosisinchinesemultiplemyeloma AT yueyunlai denovoabnormalitiesidentifiedbyfluorescenceinsituhybridizationduringfollowupconferpoorprognosisinchinesemultiplemyeloma |